---
title: "Evexta Bio and Roche plan Phase Ib trial of rupitasertib with giredestrant"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294952732.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-08-05T10:34:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294952732.md)
  - [en](https://longbridge.com/en/news/294952732.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294952732.md)
generator: "portal-rs"
---

# Evexta Bio and Roche plan Phase Ib trial of rupitasertib with giredestrant

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)

## Related News & Research

- [IDYA: Darovasertib NDA nears completion as pipeline expands with DLL3 ADC, PRMT5, and Roche collaborations](https://longbridge.com/en/news/298488281.md)
- [IDYA: NDA submission, ESMO data, and Roche collaborations set the stage for major oncology advances](https://longbridge.com/en/news/298633515.md)
- [OpenAI CFO Sarah Friar says ChatGPT's ads should be like 'if Google and Meta had a baby'](https://longbridge.com/en/news/298353501.md)
- [Aptar Pharma to support Aceso’s inhaled cystic fibrosis candidate’s advance](https://longbridge.com/en/news/298273759.md)
- [Simcere Zaiming licenses SIM0660 to Roche in deal worth up to $1.53 billion](https://longbridge.com/en/news/297652647.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**